PMC9618799_01
(A, B) the bone marrow smear suggested 78% lymphoplasmacytic lymphoma cells. (C) The bone marrow smear was significantly active in proliferation. Primitive cells accounted for 94.5% of the total number of cells.
fimmu-13-1001482-g001.jpg
PMC9618799_01_fimmu-13-1001482-g001.jpg
f1
The bone marrow smear suggested 78% lymphoplasmacytic cells ( Figures 1A, B ). The POX staining was negative ( Figure 1C ).
Bone marrow flow cytometry revealed an abnormal cell population occupying about 82.1% of nuclear cells, expressing CD19, CD22, and TdT. Some cells expressed HLA-DR, CD10, CD34, and CD38, not expressed cIgM, indicating abnormal naive B lymphocytes. Cells with CD45+CD19+ occupying about 8.0% of nuclear cells, expressing HLA-DR, CD19, CD20, CD22, sIgM, cIgM, cLambda, Lambda, suggested aberrant monoclonal B lymphocytes. Cells with CD45dimCD38bright occupied about 0.1% of nuclear cells, expressing CD19, CD38, CD56, CD138, CD229, cLambda, suggested aberrant monoclonal plasma cells.
fimmu-13-1001482-g002.jpg
PMC9618799_01_fimmu-13-1001482-g002.jpg
f2
CD34, and CD38, not expressed cIgM, indicating abnormal naive B lymphocytes. Cells with CD45+CD19+ occupying about 8.0% of nuclear cells, expressing HLA-DR, CD19, CD20, CD22, sIgM, cIgM, cLambda, Lambda, suggested aberrant monoclonal B lymphocytes. Cells with CD45dimCD38bright occupied about 0.1% of nuclear cells, expressing CD19, CD38, CD56, CD138, CD229, and cLambda, suggesting aberrant monoclonal plasma cells ( Figure 2 ).
The treatment timeline of the patient.
fimmu-13-1001482-g003.jpg
PMC9618799_01_fimmu-13-1001482-g003.jpg
f3
Therefore, only zanubrutinib was administered as maintenance therapy ( Figure 3 ).